Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 30, 2024 | $0.20 | 2024-06-14 | 2024-06-15 |
| May 31, 2024 | $0.20 | 2024-05-14 | 2024-05-15 |
| April 30, 2024 | $0.20 | 2024-04-12 | 2024-04-15 |
| March 31, 2024 | $0.20 | 2024-03-14 | 2024-03-15 |
| February 29, 2024 | $0.20 | 2024-02-14 | 2024-02-15 |
Dividends Summary
- Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock has issued 58 dividend payments over the past 6 years
- The most recent dividend was paid 447 days ago, on June 30, 2024
- The highest dividend payed out to investors during this period was $0.5859375 per share
- The average dividend paid during this period was $0.26 per share.
Company News
Fortress Biotech announced the closing of the sale of its subsidiary Checkpoint Therapeutics to Sun Pharmaceutical Industries Limited. The transaction will generate approximately $28 million for Fortress and a 2.5% royalty on net sales of Checkpoint's FDA-approved drug UNLOXCYT.
Fortress Biotech, an innovative biopharmaceutical company, announced the FDA approval of its drug Emrosi for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway. The company also announced a strategic collaboration with Partex NV to accelerate asset identification and evaluation using Partex's proprietary AI platform.
Fortress Biotech CEO Dr. Lindsay A. Rosenwald has increased his stake in the company by purchasing $36.7k worth of Series A Cumulative Perpetual Preferred Stock. This move demonstrates the CEO's confidence in the company's future prospects.